Six readers
| reader | found | score |
|---|---|---|
| genetics Open Targets | no genetic evidence; overall 0.01 from other evidence | 0.00 |
| cell type Human Protein Atlas | expressed broadly, no clear home in brain cells | 0.40 |
| chemistry Open Targets | reachable by antibody | 0.36 |
| trials ClinicalTrials.gov | no Parkinson's trials on record: an open field | 1.00 |
| literature PubMed | no papers tie it to Parkinson's yet | 1.00 |
| pathways Reactome | 2 pathways; mostly vesicle traffic | 1.00 |
No case: the score is under the bar. Receipt 10795
Sealed predictions
- MAN1A2 in dopamine neurons, braak+0.58 (p 0.102) → -0.46 (p 0.212)receipt 10803
Swarm cases
receipt 10803: MAN1A2 in dopamine neurons, braak
- power
- full sample +0.12 (p 0.646, n 18), 95% CI -0.37 to +0.55. the interval is wide: not enough donors to tell.
- confounder
- adjusted for sex: +0.27 (p 0.277, n 18). does not hold up.
- composition
- dopamine neurons share of nuclei vs axis +0.05 (p 0.854); controlling for it: +0.34 (p 0.170, n 18). could be the mix.
- skeptic
- leave-one-out range +0.01 to +0.25, sign flips 0; without severely affected donors +0.12 (p 0.646, n 18). fragile.
- cell type
- strongest in oligodendrocytes: +0.61 (p 0.0067, n 18) vs +0.12 in dopamine neurons. proposing oligodendrocytes.
- axis
- no measure beats "tracks Braak Lewy-body stage" for MAN1A2 in dopamine neurons.
follow-up registered; not confirmed in substantia nigra, an independent cohort.
follow-up MAN1A2 · oligodendrocytes · braak: substantia nigra, an independent cohort (Parkinson's or LBD vs controls) +0.43 p 0.131 (needs p < 2.0e-4)
Receipts
loading the receipts